Venture Partners at Boulder News
Solid Power, an industry-leading producer of all solid-state batteries for electric vehicles, announced a $130M Series B investment round, positioning them to produce full-scale batteries and expand in-house production for future vehicle integration.
As synthetic biology continues to grow, advanced benchtop systems are making research and product development easier. Now, Inscripta has announced the first commercial shipment of its groundbreaking, fully-automated Onyx platform.
OnKure develops best-in-class, targeted oncology therapeutics. New financing will be used to further clinical development of the company’s next-gen histone deacetylase (HDAC) inhibitors and fund a growing pipeline of earlier-stage molecules.
From February 16-18, 2021, Venture Partners will host the biggest Destination Startup® yet, showcasing 25 startups from 10 different universities across six states in the Rocky Mountain region—not just Colorado—and drawing investors from around the world.
The National Academy of Inventors (NAI) has announced that Boulder researchers Mark Rentschler, Greg Rieker and Tin Tin Su have been designated as NAI Senior Members in recognition of their impact on society through extraordinary innovation.
From February 16-18, 2021, Venture Partners will host the biggest Destination Startup® yet, showcasing 26 startups from 10 different universities across six states in the Rocky Mountain region—not just Colorado—and drawing investors from around the world.
Judges from the local entrepreneurial ecosystem awarded a record total of 12 grants—up to $125,000 each—for the top physical science, engineering and bioscience innovations demonstrating high commercial potential, a clear path to a compelling market and strong scientific support.
Through the Lab Venture Challenge, Venture Partners at Boulder funds the university's top innovations addressing a commercial need, with a clear path to a compelling market and strong scientific support. This showcase is a can't-miss event to see breakthrough innovations.
MyoKardia, a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, was co-founded by Leslie Leinwand, Distinguished Professor of Molecular, Cellular, and Developmental Biology at Boulder's BioFrontiers Institute.
In September, the Yidan Prize Foundation awarded Carl Wieman the prestigious Yidan Prize in Education Research for his “contribution in developing new techniques and tools in STEM education.” Wieman will use prize and project money to support Boulder’s award-winning PhET Interactive Simulations.